Nathaniel Lash

A week after the sudden shutdown of the city of Philadelphia, reported crime has dropped to some of the lowest levels seen in years, according to an Inquirer analysis of preliminary incident data.

Pennsylvania’s ICU units will need 2.5 to 7 times the number of beds they can likely make available, a new estimate shows. Just how great the need is will depend on how much of the population the virus ends up infecting — and how quickly.

“We recognized the many ways he made Temple better by naming the Richard J. Fox School of Business and Management in his honor; but the truth is he honored us with his time, his dedication and his ongoing support,” said Temple President Richard Englert.

It’s an antiquated system that can be comically inefficient, plagued by vague and conflicting policies and shoddy recordkeeping.

The city and CDC concluded patient medical records were not compromised in a breach discovered in October. The Inquirer notified the city before others could access the data.

An Inquirer analysis of federal records of OxyContin shipments brings to light, for the first time, the Philadelphia retailers who were buying the drug — and how much of it was likely being abused.

An interactive graphic delves into millions of recently unsealed records to show how Philadelphia's orders for OxyContin surged and then receded immediately after the drug was made harder to crush and snort. The pattern — a red flag for rampant abuse — was driven by just a handful of pharmacies.

Over several years, state inspectors accused the homes run by State Rep. Movita Johnson-Harrell's nonprofit of infractions including disrepair, mismanaging residents’ finances and errors in administering residents’ medications, records obtained by The Inquirer show.

The data was accessible through an online portal. It is not clear how many people may have seen it.

Pa. officials found that Pediatric Specialty Care, a facility for medically fragile children in Philadelphia’s East Falls, had staffing issues “conducive to serious injury or death,” which the company disputed.